Sugi Predict

Sugi Predict / Compounds / SCHEMBL29680713

SCHEMBL29680713

SCHEMBL29680713

C=C1CO[C@@H](CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.37
▸ THRB P10828 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.35
▸ EPHA2 P29317 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ RORC P51449 3/20 0.35
▸ LMNA P02545 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ SMYD2 Q9NRG4 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ HPGDS O60760 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31299259 1.00 NAMPT (0.37) NAMPTTHRBGAASMN1; SMN2GPR119
SCHEMBL31299244 0.89 NAMPT (0.37) NAMPTTHRBGAASMN1; SMN2GPR119
SCHEMBL29680617 0.89 NAMPT (0.37) NAMPTTHRBGAASMN1; SMN2GPR119
SCHEMBL553857 0.84 EPHA2 (0.45) THRBGAASMN1; SMN2GPR119EPHA2
SCHEMBL553856 0.84 EPHA2 (0.45) THRBGAASMN1; SMN2GPR119EPHA2
SCHEMBL30738982 0.84 NR1H2 (0.34) NAMPTTHRBGAASMN1; SMN2EPHA2
SCHEMBL29579871 0.81 PTPN1 (0.40) NAMPTTHRBGAASMN1; SMN2GPR119
SCHEMBL29579140 0.81 PTPN1 (0.40) NAMPTTHRBGAASMN1; SMN2GPR119
SCHEMBL29680582 0.81 RORC (0.41) NAMPTTHRBGAASMN1; SMN2GPR119
SCHEMBL29679782 0.81 RORC (0.41) NAMPTTHRBGAASMN1; SMN2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-12398154-B2 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2025-08-26 — — US disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 — — EP disclosed
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS NAMPT 1397/4885THRB 3031/4885GAA 3182/4885
US-12398154-B2 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS NAMPT 1397/4885THRB 3031/4885GAA 3182/4885
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS NAMPT 4746/4885THRB 1786/4885GAA 4504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.